Quarterly Result13 May 2025, 04:28 pm
GSK Pharmaceuticals Reports 9% Revenue Growth and 32% Profit Increase for FY2025
AI Summary
GlaxoSmithKline (GSK) Pharmaceuticals Limited announced its financial results for the year ended March 31, 2025. The company reported full year revenue of Rs. 3723 crores, a growth of 9%. Profit After Tax before exceptional items increased by 32% to Rs. 915 crores and EBITDA margins increased by 500 basis points (bps) to 31.4%. Key brands including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy have played a significant role in driving growth throughout the year. The company is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer.
Key Highlights
- 9% growth in full year revenue
- 32% increase in Profit After Tax before exceptional items
- 500 bps increase in EBITDA margins
- Key brands such as Augmentin, Calpol, Ceftum, T-Bact, and Trelegy driving growth
- On track to launch oncology assets Zejula and Jemperli